USPTO Patent Grants - Organic Chemistry (C07D)

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.

USPTO Patent US12583849B2 for KCNT1 Inhibitors

The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.

USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections

The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.

USPTO Patent Grant for Fluorinated Pyrimidine Compound Production

The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.

USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors

The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.

USPTO Patent Grant for Trinucleotide Repeat Disease Treatment

The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.

USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors

The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.

USPTO Patent US12583838B2 for Kinase Inhibitors

The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.

USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug

The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.

USPTO Patent Grant for Insomnia and Depression Compound

The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.

USPTO Patent US12583840B2 for Androgen Receptor Antagonists Preparation

The USPTO has granted patent US12583840B2 to Orion Corporation for a method of preparing androgen receptor antagonists and their intermediates. The patent details a process using a heterogeneous palladium catalyst for the preparation of a specific benzonitrile compound useful in the synthesis of carboxamide-structured androgen receptor antagonists.

USPTO Patent Grant: PD-L1 Antagonist Compound

The USPTO has granted a patent (US12583839B2) to ADLAI NORTYE BIOPHARMA CO., LTD. for a PD-L1 antagonist compound and its pharmaceutical composition. The patent covers compounds of Formula (I) and their use in treating immune-related disorders.

USPTO Patent Grant: Bacterial Infection Treatment Compound

The USPTO has granted a patent (US12583834B2) for a compound and pharmaceutical composition designed to treat bacterial infections by inhibiting Mfd activity. The patent was filed on February 19, 2021, and is assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT.

USPTO Patent Grant: Diastereomer-Enriched Odorant Mixture Preparation

The USPTO has granted patent US12583833B2 to Symrise AG for a distillative process to prepare a diastereomer-enriched odorant mixture. The patent covers the process, the enriched mixture, and its use in perfumery to impart or enhance floral odor notes.

USPTO Patent Grant US12583831B2 for Hydrogenation Processes

The USPTO has granted patent US12583831B2 to Archer-Daniels-Midland Company for selective hydrogenation processes and catalysts. The patent covers methods for upgrading impure feedstocks, such as those derived from biomass, to increase the concentration of valuable intermediates like glycolaldehyde and hydroxyacetone.

USPTO Patent Grant: Oxetane Derivative Synthesis Method by Microreactor

The USPTO has granted a patent (US12583830B2) for a microreactor-based synthesis method for oxetane derivatives. The patent, assigned to Changzhou Tronly Advanced Electronic Materials Co., Ltd., details a process that improves efficiency, yield, and safety compared to traditional methods.

USPTO Patent US12583828B2: Aromatic Carbonyl Compounds Preparation Process

The USPTO has granted patent US12583828B2 to BASF SE for a process to prepare aromatic carbonyl compounds. The patent describes a catalytic oxidation method using molecular oxygen, a cobalt(II) salt, and N,N′,N″-trihydroxyisocyanuric acid (THICA).

USPTO Patent Grant: Process for Ethyleneamines and Ethanolamines Manufacture

The USPTO has granted patent US12583827B2 to BASF SE for a new process to manufacture ethyleneamines and ethanolamines. The patent details a two-step process involving the conversion of glycolaldehyde derivatives and an aminating agent, followed by hydrogenation.

USPTO Patent for Acetic Acid Derivatives as Safeners

The USPTO has granted a patent (US12583826B2) to Bayer Aktiengesellschaft for acetic acid derivatives and salts thereof, intended for use as safeners in crop protection compositions. These compounds aim to reduce the phytotoxic effects of agrochemicals, particularly herbicides.

Redona Therapeutics Cancer Treatment Compounds Patent Grant

The USPTO has granted Redona Therapeutics, Inc. a patent (US12583825B2) for novel cancer treatment compounds. The patent covers specific benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives and their use in treating neoplastic diseases.

USPTO Patent Grant: Benzylamine Derivative for Anti-Tumor Efficacy

The USPTO has granted a patent (US12583822B2) to the Academy of Military Medical Sciences for a benzylamine derivative with potential anti-tumor efficacy. The patent covers the derivative, its preparation method, and its use in treating PD-1/PD-L1-related diseases.

Omecamtiv Mecarbil Salt and Preparation Process

The USPTO has granted US Patent 12583821B2 to Cytokinetics, Inc. for a specific salt form of omecamtiv mecarbil and its preparation process. This patent covers the dihydrochloride salt form, related compositions, and methods of use, primarily impacting pharmaceutical development and intellectual property.

USPTO Patent US12583820B2: Antivirals against coronavirus

The USPTO has granted patent US12583820B2 to Kansas State University Research Foundation for broad spectrum antivirals against coronaviruses. The patent covers specific chemical compounds designed to inhibit viral replication.

Biomaterial with functionalized tyrosine, preparation method, pharmaceutical composition

The USPTO has granted a patent (US12583818B2) for a method to prepare a biomaterial with selectively functionalized tyrosine and a pharmaceutical composition containing it. This innovation aims to improve the efficacy of biomaterial drugs by ensuring selective coupling to tyrosine without affecting other amino acids or the biomaterial's inherent activity.

USPTO Patent Grant US12582652B2 for Ion Channel Modulator

The USPTO has granted patent US12582652B2 to Praxis Precision Medicines, Inc. for a novel ion channel modulator compound. The patent covers methods of treating neurological disorders and conditions associated with neuronal excitability.

USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators

The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.

USPTO Patent Grant US12581852B2 for Luminescent Material

The United States Patent and Trademark Office (USPTO) has granted patent US12581852B2 to KYULUX, INC. for a compound useful as a light-emitting material. The patent covers specific chemical formulas and their application in organic optical devices.

Samsung Display Patent for Organic Compound Sensor Display

The USPTO has granted Samsung Display Co., Ltd. a patent for an organic compound sensor display. The patent, US12581853B2, covers an organic compound represented by Chemical Formula 1 and its application in sensor-embedded display panels and electronic devices. The filing date was September 28, 2022.

USPTO Patent Grant for Light-Emitting Element

The USPTO has granted patent US12581794B2 for a light-emitting element developed by Semiconductor Energy Laboratory Co., Ltd. The patent covers a specific design for a light-emitting element utilizing a phosphorescent compound and an exciplex formed by organic compounds.

USPTO Patent Grant: Bioprobes for Amine Oxidase Enzymes

The USPTO has granted a patent (US12578335B2) to Syntara Limited for novel bioprobes designed to detect and quantify amine oxidase enzymes. These bioprobes are intended for use in assessing enzyme concentrations and inhibition levels in various samples.